Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 16/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773999 | 0.89 | HRH4 (0.65) | HRH4HRH3AURKAPDPK1AURKB | |
| SCHEMBL12604970 | 0.88 | HRH4 (0.59) | HRH4HRH3AURKAPDPK1AURKB | |
| SCHEMBL1775872 | 0.85 | HRH4 (0.57) | HRH4HRH3KCNH2 | |
| SCHEMBL1775160 | 0.84 | HRH4 (0.53) | HRH4HRH3KCNH2 | |
| SCHEMBL1775313 | 0.83 | HRH4 (0.53) | HRH4HRH3KCNH2 | |
| SCHEMBL1774217 | 0.83 | HRH4 (0.53) | HRH4HRH3KCNH2 | |
| SCHEMBL1775397 | 0.81 | HRH4 (0.54) | HRH4HRH3 | |
| SCHEMBL1776133 | 0.80 | HRH4 (0.64) | HRH4HRH3KCNH2 | |
| SCHEMBL1774659 | 0.80 | HRH4 (0.77) | HRH4HRH3KCNH2 | |
| SCHEMBL1775731 | 0.79 | HRH4 (0.69) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885HRH3 187/4885AURKA 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.